

Together completes a successful bond offering:

The offer was oversubscribed with demand of about NIS 57 million (nominal value). That's over 2.2 times the NIS 25.2 million that the company raised, at a closing price of NIS 951 for NIS 1,000 (nominal value) – significantly higher than the minimum price

Ashkelon, February 6, 2020 - Together (TASE: TGDR), which specializes in cultivating and producing medical cannabis products, has reported a successful convertible bond offering – the completed offering raised NIS 25.2 million.

The company sought to raise NIS 26 million (nominal value) and the offering was oversubscribed with demand of about NIS 57 million (nominal value) 2.2 times the amount sought. Furthermore, the minimum price for the offering was NIS 910 for every NIS 1,000 (nominal value) and the closing price stood at NIS 951 – significantly higher than the minimum price. Due to the closing price, the discount rate at which the bond was issued was 4.9%.

Together Chairman Yohanan Danino: "The results of the offering are an exceptional vote of confidence in Together, which has shown that it is impressively meeting its business plans since the day it was founded."

The bonds include a lien on the revenue from sales contracts in Israel signed as of January 8, 2020, which will be directly deposited into the trustees account that will be held in security for the bondholders. The aforementioned revenue resulting from the five agreements have been signed with the companies: Cannabis Laboratories, Panaxia, Teva Adir, Univo and Cannabliss (a subsidiary). These revenues amount to more than NIS 224 million, of which NIS 48.50 million is expected in 2020.

The bond offering was led by Apex Issuances managed by Eliav Bar-David and Aharon Samra and Adv. Ilan Gerzi, Nir Zohar, and Hilla Shaanani from the Pearl Choen Zedek Latzer Baratz law firm.

Together has begun commercial operations from its farm in Israel, after receiving IMC-GAP approval. The facility in Ashkelon covers five acres, one of the largest in Israel, and allows the company to cultivate large amounts of medical cannabis produce. Together's medical cannabis products will be available in pharmacies stores and for medical cannabis patients in Israel, who in recent months have suffered a severe shortage of products. The company plans bringing the farm in Ashkelon to high production capacity and to sign additional commercial agreements.

In addition, the company has a large actively operating cultivation facility covering 7.5 acres in Uganda that has received GACP authorization and has begun harvesting a second crop. The facility meets the WorldHealth Organization Good Agricultural and Collection Practices (GACP)

guidelines for agricultural cultivation for medical use which complies with the standards and regulations approved and recognized in Europe.

In addition, Together has reported receiving official letters from the National Drug Authority in Uganda which are addressed to the Minister of Health in Malta, the Minister of Health in Germany and the Minister of Health in Israel and confirm that Industrial Globus Uganda is permitted to export medical cannabis to Malta, Germany and Israel. This is after the National Drug Authority will examine and determine that the medical cannabis, which it is being requested to export, meets the standards required for medical cannabis by an independent laboratory in Uganda or outside of Uganda.

Alongside its pharmaceutical operations, Together is also active in the CBD cosmetics based sector together with Premier Dead Sea. The company plans through its Dutch production company, which has the appropriate approvals, to produce thousands of units of three approved products, which will be distributed to sale at distribution points in countries in which the sale of products is legal.

About Together and Globus Pharma

Together (TASE: TGDR) is active in the field of medical cannabis through its subsidiary Globus Pharma, which is currently developing an advanced agricultural and technological infrastructure for the growing, production and marketing of medical cannabis products in Israel and abroad. The Company has marketing and distribution agreements with leading medical cannabis companies in Germany and Canada, with a total volume of approximately 80 tons of produce annually. Together Pharma has a team of experts in growing cannabis with more than 20 years of knowledge and experience in the practical growing of cannabis and the Company is in advanced stages of receiving marketing approval in Germany and the entire European market, including the filing of an application for obtaining European export permit of medical cannabis products and obtaining a license to distribute them throughout Europe.

<https://together-pharma.com>